SightfileU.S. market data from official filings

MONTE ROSA THERAPEUTICS INC (GLUE)

Name: MONTE ROSA THERAPEUTICS INC (GLUE) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001826457 · EDGAR filings · Updated 2026-07-17

MONTE ROSA THERAPEUTICS INC (GLUE) has reported institutional ownership of 108.7%, with 189 institutional managers holding positions valued at $1.43B per the latest 13F reporting period.

Institutional ownership

108.7%

Institutional managers

189

Reported 13F value

$1.43B

Insider activity

22 trans.

−$1.24M net selling

Latest updates

2026-07-17 — Insider transaction reported (Form 4)
2026-07-16 — Insider transaction reported (Form 4)
2026-07-16 — Notice of proposed sale filed (Form 144)
2026-07-15 — Notice of proposed sale filed (Form 144)
2026-07-08 — SCHEDULE 13G/A filed
2026-07-07 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, MONTE ROSA THERAPEUTICS INC has 189 institutional holders and institutional ownership of 108.7%.

Insider activity

Insiders reported 22 transactions (0 buys, 15 sells) across 6 reporting insiders, with a net reported value of −$1.24M.

Related companies

DEFINIUM THERAPEUTICS F (DFTX) · ATRICURE INC (ATRC) · DAMORA THERAPEUTICS INC (DMRA) · BELITE BIO INC (BLTE) · INTELLIA THERAPEUTICS INC (NTLA) · Procept Biorobotics Corp (PRCT)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-17.